251 related articles for article (PubMed ID: 28639970)
21. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
[TBL] [Abstract][Full Text] [Related]
22. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients.
Oral A; Sahin T; Turker F; Kocak E
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31533345
[No Abstract] [Full Text] [Related]
23. The prevalence of nonalcoholic fatty liver disease and relationship with serum uric acid level in Uyghur population.
Cai W; Song JM; Zhang B; Sun YP; Yao H; Zhang YX
ScientificWorldJournal; 2014; 2014():393628. PubMed ID: 24516367
[TBL] [Abstract][Full Text] [Related]
24. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center.
Sandra S; Lesmana CRA; Purnamasari D; Kurniawan J; Gani RA
Diabetes Metab Syndr; 2019; 13(1):424-428. PubMed ID: 30641737
[TBL] [Abstract][Full Text] [Related]
25. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
26. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Xu C; Wan X; Xu L; Weng H; Yan M; Miao M; Sun Y; Xu G; Dooley S; Li Y; Yu C
J Hepatol; 2015 Jun; 62(6):1412-9. PubMed ID: 25623823
[TBL] [Abstract][Full Text] [Related]
27. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
28. Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.
Jamali R; Razavizade M; Arj A; Aarabi MH
World J Gastroenterol; 2016 Jun; 22(21):5096-103. PubMed ID: 27275102
[TBL] [Abstract][Full Text] [Related]
29. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults.
Liu CQ; He CM; Chen N; Wang D; Shi X; Liu Y; Zeng X; Yan B; Liu S; Yang S; Li X; Li X; Li Z
Sci Rep; 2016 Dec; 6():38605. PubMed ID: 27924915
[TBL] [Abstract][Full Text] [Related]
30. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity.
Zhu WH; Fang LZ; Lu CR; Dai HL; Chen JH; Qiao QH; Chen LY
World J Gastroenterol; 2015 Sep; 21(35):10192-9. PubMed ID: 26401084
[TBL] [Abstract][Full Text] [Related]
31. Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease.
Sun DQ; Wu SJ; Liu WY; Lu QD; Zhu GQ; Shi KQ; Braddock M; Song D; Zheng MH
Expert Opin Ther Targets; 2016; 20(3):375-87. PubMed ID: 26419119
[TBL] [Abstract][Full Text] [Related]
32. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
33. Association between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.
Darmawan G; Hamijoyo L; Hasan I
Acta Med Indones; 2017 Apr; 49(2):136-147. PubMed ID: 28790228
[TBL] [Abstract][Full Text] [Related]
34. Association between gastroesophageal reflux disease and nonalcoholic fatty liver disease: A meta-analysis.
Wijarnpreecha K; Panjawatanan P; Thongprayoon C; Jaruvongvanich V; Ungprasert P
Saudi J Gastroenterol; 2017; 23(6):311-317. PubMed ID: 29205182
[TBL] [Abstract][Full Text] [Related]
35. Associations of hyperuricemia and obesity with remission of nonalcoholic fatty liver disease among Chinese men: A retrospective cohort study.
Yang C; Yang S; Feng C; Zhang C; Xu W; Zhang L; Yan Y; Deng J; Ohore OE; Li J
PLoS One; 2018; 13(2):e0192396. PubMed ID: 29415050
[TBL] [Abstract][Full Text] [Related]
36. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
38. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
39. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia.
Zhang S; Du T; Li M; Lu H; Lin X; Yu X
Medicine (Baltimore); 2017 Mar; 96(12):e6381. PubMed ID: 28328829
[TBL] [Abstract][Full Text] [Related]
40. Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.
Xu C
Hepatol Int; 2016 Mar; 10(2):286-93. PubMed ID: 26671825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
